UNSPSC 51321902: Eflucimibe

This classification denotes an anti-lipidemic agent with the molecular formula C29H43NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3DK1X2C37M, chemically known as (s)-2,3,5-trimethyl-4-hydroxy-alpha-dodecylthioacetanilide but generally known as eflucimibe, which bears US NIH Compound Identifier 3025954. The term EFLUCIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule eflucimibe under HS 29309085 and SITC 51549.

As of Q4 2014, EFLUCIMIBE remains the US FDA Preferred Term for this commodity. Eflucimibe bears US NLM identifiers UMLS ID C0963171 and NCI Concept Code C75995. SMILES: CCCCCCCCCCCCCC(=S)NC1=C(C(=C(C(=C1)C)O)C)C.

UNSPSC 51321902 Eflucimibe, a Commodity code, covers pharmaceutical products, though recent state and local solicitations under this code indicate that state and local governments are procuring a broader range of medications and pharmaceutical products — primarily generic multi-source pharmaceuticals, over-the-counter products, and advanced life support medications for emergency medical services. State and local issuing bodies soliciting under this code include municipal fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Vendors supplying under this code typically work through authorized pharmaceutical wholesalers and must comply with cGMP certification, Drug Supply Chain Security Act requirements, FDA standards, OSHA Hazard Communication Standards for Safety Data Sheets, and federal accessibility standards such as WCAG 2.2 Level AA and Section 508.

Recent activity is concentrated in Texas, Minnesota (serving Oregon and other participating states), and Florida. Representative recent opportunities include the City of Tampa Fire Rescue's sealed-bid procurement (26P00188) for four advanced life support medication line items — Labetalol, Epinephrine, Adenosine, and Diltiazem — with a response deadline of April 8, 2026 and estimated contract value of $40,000, posted through the OpenGov eProcurement Portal with a Small Local Business Enterprise sheltered-market 5 percent bid discount; the Texas Health and Human Services Commission's Request for Information (HHS0017013) seeking vendor capabilities for direct-to-manufacturer prescription fulfillment, posted April 3, 2026; and MMCAP's Request for Proposal (S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring distribution through AmerisourceBergen, Cardinal Health, or Morris & Dickson with contract term effective July 1, 2026. MMCAP contracts carry a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.